BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11917576)

  • 1. Validation of AutoPap primary screening system sensitivity and high-risk performance.
    Tench WD
    Acta Cytol; 2002; 46(2):296-302. PubMed ID: 11917576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of high grade squamous intraepithelial lesions and tumors using the AutoPap System: results of a primary screening clinical trial.
    Wilbur DC; Prey MU; Miller WM; Pawlick GF; Colgan TJ; Dax Taylor D
    Cancer; 1999 Dec; 87(6):354-8. PubMed ID: 10603189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AutoPap 300 QC System multicenter clinical trials for use in quality control rescreening of cervical smears: II. Prospective and archival sensitivity studies.
    Patten SF; Lee JS; Wilbur DC; Bonfiglio TA; Colgan TJ; Richart RM; Cramer H; Moinuddin S
    Cancer; 1997 Dec; 81(6):343-7. PubMed ID: 9438459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The AutoPap system for primary screening in cervical cytology. Comparing the results of a prospective, intended-use study with routine manual practice.
    Wilbur DC; Prey MU; Miller WM; Pawlick GF; Colgan TJ
    Acta Cytol; 1998; 42(1):214-20. PubMed ID: 9479343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity studies of AutoPap System Location-Guided Screening of cervical-vaginal cytologic smears.
    Huang TW; Lin TS; Lee JS
    Acta Cytol; 1999; 43(3):363-8. PubMed ID: 10349363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A feasibility study of the AutoPap system location-guided screening.
    Lee JS; Kuan L; Oh S; Patten FW; Wilbur DC
    Acta Cytol; 1998; 42(1):221-6. PubMed ID: 9479344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of the AutoPap Primary Screening System in the detection of high-risk cases in cervicovaginal smears.
    Alasio LM; Alphandery C; Grassi P; Ruggeri M; De Palo G; Pilotti S
    Acta Cytol; 2001; 45(5):704-8. PubMed ID: 11575647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical endocervical glandular cells: accuracy of cytologic diagnosis.
    Lee KR; Manna EA; St John T
    Diagn Cytopathol; 1995 Oct; 13(3):202-8. PubMed ID: 8575278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The AutoPap 300 QC System multicenter clinical trials for use in quality control rescreening of cervical smears: I. A prospective intended use study.
    Patten SF; Lee JS; Wilbur DC; Bonfiglio TA; Colgan TJ; Richart RM; Cramer H; Moinuddin S
    Cancer; 1997 Dec; 81(6):337-42. PubMed ID: 9438458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A feasibility study of the use of the AutoPap screening system as a primary screening and location-guided rescreening device.
    Confortini M; Bonardi L; Bulgaresi P; Cariaggi MP; Cecchini S; Ciatto S; Cipparrone I; Galanti L; Maddau C; Matucci M; Rubeca T; Troni GM; Turco P; Zappa M; Carozzi F
    Cancer; 2003 Jun; 99(3):129-34. PubMed ID: 12811852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of the Papanicolaou smear diagnosis of low-grade squamous intraepithelial lesion cannot exclude high-grade squamous intraepithelial lesion.
    Nasser SM; Cibas ES; Crum CP; Faquin WC
    Cancer; 2003 Oct; 99(5):272-6. PubMed ID: 14579293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does use of the AutoPap assisted primary screener improve cytologic diagnosis?
    Bibbo M; Hawthorne C; Zimmerman B
    Acta Cytol; 1999; 43(1):23-6. PubMed ID: 9987445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer.
    Ge Y; Christensen P; Luna E; Armylagos D; Schwartz MR; Mody DR
    Cancer Cytopathol; 2017 Aug; 125(8):652-657. PubMed ID: 28574670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The primary screening clinical trials of the TriPath AutoPap System.
    Wilbur DC; Norton MK
    Epidemiology; 2002 May; 13 Suppl 3():S30-3. PubMed ID: 12071481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenocarcinoma in situ of the cervix.
    Schoolland M; Segal A; Allpress S; Miranda A; Frost FA; Sterrett GF
    Cancer; 2002 Dec; 96(6):330-7. PubMed ID: 12478680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical importance of "low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion (LSIL-H)" terminology for cervical smears 5-year analysis of the positive predictive value of LSIL-H compared with ASC-H, LSIL, and HSIL in the detection of high-grade cervical lesions with a review of the literature.
    Ince U; Aydin O; Peker O
    Gynecol Oncol; 2011 Apr; 121(1):152-6. PubMed ID: 21211831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative sensitivities of ThinPrep and Papanicolaou smear for adenocarcinoma in situ (AIS) and combined AIS/high-grade squamous intraepithelial lesion (HSIL): comparison with HSIL.
    Roberts JM; Thurloe JK
    Cancer; 2007 Dec; 111(6):482-6. PubMed ID: 17969065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytologic features of high grade squamous intraepithelial lesions involving endocervical glands on thin-layer cytology.
    Selvaggi SM
    Acta Cytol; 2005; 49(6):689-90. PubMed ID: 16450913
    [No Abstract]   [Full Text] [Related]  

  • 19. Whole-Slide Imaging of Pap Cellblock Preparations Is a Potentially Valid Screening Method.
    Tawfik O; Davis M; Dillon S; Tawfik L; Diaz FJ; Amin K; Fan F
    Acta Cytol; 2015; 59(2):187-200. PubMed ID: 25967603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved quality-control detection of false-negative Pap smears using the Autopap 300 QC system.
    Marshall CJ; Rowe L; Bentz JS
    Diagn Cytopathol; 1999 Mar; 20(3):170-4. PubMed ID: 10086244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.